Indexed in Journament

cancer

ISSN 1097-0142· EN

Journal Website Certificate of Indexing
Login or register to claim ownership or editorship of this journal.
41.4 / 100
Journament Score
Below Average
Ranked #1,490 of 29,297 scored journals (34,016 indexed)
32 Articles
Scores higher than 94.9% of scored journals
050100
The Journament Score is computed from platform statistics — reader engagement, accessibility, publication timeliness, keyword breadth, community impact and content distribution — into a single 0–100 figure, recalculated as new articles and metadata are indexed. Dimensions that cannot be measured for this journal are excluded rather than estimated. It is independent of the paid AI Quality Analysis, which never affects this score or the ranking. Full methodology →

About This Journal

Short Name cancer
Abbreviated Name cancer
ISSN 1097-0142
URL http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142

Quality Profile

7 of 12 dimensions measured
This journal Average of scored journals
Platform statistics — the free Journament Score AI Quality Analysis — separate paid product, ranks nothing

5 of the 12 dimensions could not be measured for this journal. They are left as gaps in the shape rather than plotted as zero.

Show the numbers
Dimension This journal Corpus average
Engagement 31.1 30.5
Accessibility 20.0 23.1
Timeliness 0.0 3.0
Diversity 69.7 26.4
Innovation 70.0 24.1
Community Impact 9.3 4.5
Content Distribution 78.1 89.3
Content Quality — 55.1
Ethics & Transparency — 40.5
Editorial Standards — 33.0
Publication Regularity — 52.9
Geographic Reach — 30.4

Publications Per Year

Articles (32)

2019
Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3-arm pilot randomized controlled trial.
Johns, Shelley A;Stutz, Patrick V;Talib, Tasneem L;Cohee, Andrea A;Beck-Coon, Kathleen A;Brown, Linda F;Wilhelm, Laura R;Monahan, Patrick O;LaPradd, Michelle L;Champion, Victoria L;Miller, Kathy D;Giesler, R Brian;
561 views DOI Abstract
2000
A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma
Kathy D. Miller,Nikhil Munshi,David Loesch,Lawrence H. Einhorn M.D.,George W. Sledge;Kathy D. Miller;Nikhil Munshi;David Loesch;Lawrence H. Einhorn M.D.;George W. Sledge;
Vol. 88 , No. 2 , pp. 375-380
446 views DOI Abstract
2006
Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions
Safdar A;Rodriguez GH;Lichtiger B;Dickey BF;Kontoyiannis DP;Freireich EJ;Shpall EJ;Raad II;Kantarjian HM;Champlin RE;;
Vol. 106 , No. 12 , pp. -
434 views Abstract
2020
Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.
Li, Ang;Carlson, Josh J;Kuderer, Nicole M;Schaefer, Jordan K;Li, Shan;Garcia, David A;Khorana, Alok A;Carrier, Marc;Lyman, Gary H;
429 views DOI Abstract
2019
Utilization pattern and service settings of palliative care for patients with metastatic non-small-cell lung cancer.
Huo, Jinhai;Hong, Young-Rock;Turner, Kea;Bian, Jiang;Grewal, Reetu;Wilkie, Diana J;
429 views DOI Abstract
2018
Impact of the insurance type of head and neck cancer patients on their hospitalization utilization patterns.
Gupta, Avni;Sonis, Stephen T;Schneider, Eric B;Villa, Alessandro;
Vol. 124 , No. 4 , pp. 760-768
421 views DOI Abstract
2010
Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer
Chadha, M.
Vol. 116 , pp. 2132-2139
414 views DOI
2019
Physicians' perspectives on medication adherence and health promotion among cancer survivors.
Stump, Tammy K;Robinson, June K;Yanez, Betina;Penedo, Frank;Ezeofor, Adaeze;Kircher, Sheetal;Spring, Bonnie;
413 views DOI Abstract
2019
Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study.
Mullins, Megan A;Peres, Lauren C;Alberg, Anthony J;Bandera, Elisa V;Barnholtz-Sloan, Jill S;Bondy, Melissa L;Funkhouser, Ellen;Moorman, Patricia G;Peters, Edward S;Terry, Paul D;Schwartz, Ann G;Lawson, Andrew B;Schildkraut, Joellen M;Cote, Michele L;
411 views DOI Abstract
2020
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Zhang, Hongjing;Qian, Guoqing;Zong, Dan;Fan, Songqing;Owonikoko, Taofeek K;Ramalingam, Suresh S;Sun, Shi-Yong;
404 views DOI Abstract
2020
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
Seiwert, Tanguy Y;Kochanny, Sara;Wood, Kevin;Worden, Francis P;Adkins, Douglas;Wade, James L;Sleckman, Bethany G;Anderson, Daniel;Brisson, Ryan J;Karrison, Theodore;Stadler, Walter M;Vokes, Everett E;
349 views DOI Abstract
2020
The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma.
, ;
314 views DOI Abstract
2020
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Pal, Sumanta K;Bajorin, Dean;Dizman, Nazli;Hoffman-Censits, Jean;Quinn, David I;Petrylak, Daniel P;Galsky, Matthew D;Vaishampayan, Ulka;De Giorgi, Ugo;Gupta, Sumati;Burris, Howard A;Soifer, Harris S;Li, Gary;Wang, Hao;Dambkowski, Carl L;Moran, Susan;Daneshmand, Siamak;Rosenberg, Jonathan E;
268 views DOI Abstract
2020
Assessing the effect of patient navigator assistance for psychosocial support services on health-related quality of life in a randomized clinical trial in Latino breast, prostate, and colorectal cancer survivors
Ramirez, A.
Vol. 126 , pp. 1112-1123
302 views DOI
2020
Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century
Yadav, S.
Vol. 126 , pp. 26-36
243 views DOI
2020
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Zhang, Hongjing;Qian, Guoqing;Zong, Dan;Fan, Songqing;Owonikoko, Taofeek K;Ramalingam, Suresh S;Sun, Shi-Yong;
404 views DOI Abstract
2020
Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.
Li, Ang;Carlson, Josh J;Kuderer, Nicole M;Schaefer, Jordan K;Li, Shan;Garcia, David A;Khorana, Alok A;Carrier, Marc;Lyman, Gary H;
429 views DOI Abstract
2020
Physician and facility drivers of spending variation in locoregional prostate cancer.
Rodin, Danielle;Chien, Alyna T;Ellimoottil, Chad;Nguyen, Paul L;Kakani, Pragya;Mossanen, Matthew;Rosenthal, Meredith;Landrum, Mary Beth;Sinaiko, Anna D;
343 views DOI Abstract
2020
The efficacy of a technology-based information and coaching/support program on pain and symptoms in Asian American survivors of breast cancer
Im, E.
Vol. 126 , pp. 670-680
161 views DOI
2019
alfabetizadoras y lectura: reflexiones sobre sus concepciones y prácticas
;Lais Fernanda Espósito Barbosa;Elianeth Dias Kanthack Hernandes
Vol. 6 , No. 15 , pp. 114-133
200 views DOI Abstract
Journament Score
41.4/100 · Below Average
Ranked #1,490 of 29,297 scored
(34,016 journals indexed)
Platform Statistics
AI Quality Analysis
Separate paid analysis — does not affect ranking.
Journament

Overall Quality Score

41.4/100

Tier: Below Average

The Journament Overall Quality Score is a comprehensive metric that evaluates academic journals across multiple dimensions including engagement, accessibility, diversity, innovation, and community impact.

This score helps researchers, institutions, and publishers understand the holistic quality and impact of a journal beyond traditional metrics.

Engagement Score

31.1/100

Measures user interactions, views, citations, and community involvement with this journal's content.

Higher engagement scores indicate that the journal's content is actively being read, cited, and discussed within the academic community.

Accessibility Score

20.0/100

Evaluates how easily researchers can access journal content, including open access availability, ISSN registration, and indexing.

This metric considers factors such as paywalls, open access policies, and availability across different academic databases and search engines.

Diversity Score

69.7/100

Assesses geographic and institutional diversity of authors, editorial board composition, and topic breadth.

A diverse journal publishes work from various geographic regions, institutions, and covers a broad range of topics within its field.

Innovation Score

70.0/100

Evaluates research novelty, interdisciplinary work, and emerging topics based on AI analysis of article abstracts.

This score reflects how much the journal publishes cutting-edge research, explores new methodologies, and bridges different academic disciplines.

Community Impact Score

9.3/100

Measures scholarly contribution and real-world applications of published research.

This metric evaluates how the journal's research translates into practical applications, policy changes, and benefits to society beyond academia.

Timeliness Score

0.0/100

Evaluates recent publication activity, publication frequency, and currency of research topics.

Higher scores indicate consistent publishing schedules and timely coverage of current research trends.

Content Distribution

78.1/100

Measures how evenly reader attention spreads across the journal's articles, using the Gini coefficient of article clicks.

Higher scores mean readership is distributed across many articles rather than concentrated on one or two.

Ethics & Transparency Score

Not yet measured

Research Integrity (10% weight)

Assesses COPE standards compliance, ethical considerations in research, transparency in methodologies, and reproducibility practices.

This metric ensures the journal maintains high ethical standards and promotes transparent, trustworthy research.

Content Quality Score

Not yet measured

Academic Rigor (20% weight) + Methodology Quality (12%)

Evaluates research methodology soundness, statistical rigor, theoretical framework strength, appropriateness of research methods, data quality, and clarity & readability.

This comprehensive metric ensures published research meets the highest academic standards.

Editorial Diversity Score

Not yet measured

Author Diversity + Interdisciplinary Value (8%)

Measures geographic diversity of authors, institutional variety, editorial board composition, and cross-disciplinary connections.

Diverse editorial teams bring varied perspectives and reduce bias in academic publishing.

Publication Regularity Score

Not yet measured

Assesses consistency of publication schedule, frequency stability, and predictable output patterns.

Regular publication schedules indicate reliable journal operations and consistent workflow management.

Geographic Reach Score

Not yet measured

Evaluates international author representation, global readership distribution, and cross-border research collaboration.

Wide geographic reach indicates global impact and international recognition of the journal's research.